

Collaborative Working Project executive summary

Project title	A Collaborative Working Agreement between Sanofi and the Dermatology Department within Manchester Foundation Trust to review and improve the patient journey and experience for patients requiring a Biologic treatment.
Partner organisation/s	Manchester University NHS Foundation Trust, Cobbett House, Oxford Road, Manchester, M13 9WL Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT
Project rationale	<p>Manchester Foundation Trust Dermatology service is currently not able to prescribe any Biologic therapies which means that patients with conditions such as Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa that have not improved with Immunosuppressants and therefore require Biologic treatments must be referred to Salford care Organisation within Northern care Alliance. This has led to patients in Manchester being disadvantaged versus patients in other parts of Greater Manchester that have faster access to Biologic treatment options. The Dermatology service at Salford is under pressure to deliver its own locality targets and so the increased referrals from Manchester Foundation Trust is adding to the extended waiting times. The Dermatology department at Manchester Foundation Trust want to explore the opportunity to set up a new Biologics service and have a Biologics administrator to support delivery of the service.</p> <p>We will produce an options appraisal based on the insights we gather with recommendations and an action plan for service changes to deliver improvements in the Dermatology Service. The project will be in 2 parts. Part 1 will be to map the current service provision in terms of capacity & demand, NHS clinical resources, patient pathway and model the potential requirements based on projected increases in service usage to determine the requirements to allow for future proofing of the service 12 months after initiation. Part 1 will be completed in 1-2 months.</p> <p>Part 2 will be where Sanofi will initially fund the Biologic Administrator post with the intention of the business case providing the evidence required for the Trust to fund the role post the end of the project. In addition, Sanofi will provide Project Management support to assist with the implementation of the action plan and undertake an evaluation of the impact of the changes made after an agreed time frame. Part 2 will be funded for 12 months.</p>

Project period	Q2 2024 – Q1 2027
Project objectives	<p>The collaborative working project will deliver the following benefits for Patients, NHS and Sanofi:</p> <p>Patients:</p> <ul style="list-style-type: none"> • Improve patient experience of the service by reducing patient wait times for new patients, have their care closer to home and improved service co-ordination. • Reduction in time for patients to access biologics where this treatment is recommended. • Reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications for patients associated with their treatment. • Improved equity of access to treatment options as well as a clearer pathway of care. <p>NHS:</p> <ul style="list-style-type: none"> • Identification of the gaps and issues within the current access to the biologics service and identification of proposed changes to improve the service. • Review of capacity and demand for the biologics service to inform the development of the biologics service to support the follow-up, on-going management of current patients and future proof the service. • Supporting the optimum management of patients on immunosuppressants and biologics by organising and co-ordinating the Systemics and Biologics Service. • Review and improvement of processes for management of homecare for patients on biologics and the issue of repeat prescriptions. • Establishment and management of a biologics and immunosuppressant prescription database to ensure a high quality and accurate database in dermatology. • Development of a new Biologic service will increase the services currently offered at the Trust which will support improved outcomes in patient care and increase the opportunity to attract and maintain NHS resource within the Trust. <p>Sanofi:</p> <ul style="list-style-type: none"> • Greater clarity of the pressure points and priorities for the dermatology service enabling us to tailor our offerings in the future.

	<ul style="list-style-type: none">• Greater clarity of the gaps and problems around homecare organisation and co-ordination affecting the issue of repeat prescriptions for patients on biologics which is a common problem across Hospital Trusts thereby enabling us to explore how best to support other Hospital Trusts to address these issues.• Improved corporate reputation within Manchester Foundation Trust by supporting them to improve the quality of care for patients.• As Sanofi produce a therapy in the dermatology area, changes implemented through the project may result in an increase of use of this therapy and other therapies in line with local and national guidance. <p>This project is being completed by collating resources of approximately £63,000 (Sanofi 53%: NHS 47%)</p>
Contact details	<p><u>Manchester University NHS Foundation Trust</u> Tom Berry, Divisional Director – Medicine and Outpatients, WTWA <u>Sanofi</u> Paul Naish, Head of Market Access</p>